Answers are grounded in this paper and cite their sources.
Over 1-million people with Type 1 diabetes (T1D) live in the Western Pacific Region (WPR). Generally, estimated T1D incidence (range 0.26–15.60/100,000 persons p.a.) and prevalence are increasing. Based on the T1D index estimated healthy-life-years lost due to T1D ranges 20.6–46.0 years. Modulating factors regarding T1D epidemiology and health outcomes include ethnicity, genetics, healthcare and socioeconomic aspects. Whilst insulin pumps and continuous glucose monitors are available in many WPR countries/regions they are subsidised in only a few. Adjunct glucose drugs, developed for Type 2 diabetes if used in T1D are mainly used off-label. Regional research includes diabetes care, adjunct drugs, technology and stigma and discrimination. Stigma is common and advocacy and human rights to mitigate it are discussed. Advances will be facilitated by engaging all stakeholders, including people with diabetes, their carers and communities, clinicians, the healthcare system, payers, researchers, Non-Government Organisations, industry, government and policy-makers.
No takes yet. Share an insight, caveat, or question.
Jenkins et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: